The following were posted to the Low Dose Naltrexone website, at http://www.lowdosenaltrexone.org/ldn_latest_news.htm.
Special thanks to tireless GWI and MS advocate Nancy Rekowski for submitting this!
Successful Crohn’s Disease Trial Results Published. Jill P. Smith, MD, Professor of Gastroenterology at Pennsylvania State University's College of Medicine, and her colleagues, have published the results of their Phase II study of 40 adults with Crohn’s disease, “Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled Trial”, in the online journal Digestive Diseases and Sciences, March 8, 2011.
The 4.5mg daily dose of naltrexone proved to have very positive results, with significant improvements in the Crohn’s Disease Activity Index scores and with substantial healing demonstrated by endoscopy. (See Clinical Trials for LDN / Recently Published.)
Several Major Clinical Trials of LDN Await Publication. Three important clinical trials of LDN have each recently completed their planned studies and are now either undergoing final statistical analysis or are awaiting peer-review medical journal publication. Until that final step is achieved, we are proscribed from reporting any significant data results. However, we are pleased to observe that various useful outcomes will be reported by all three. The trials involved:
- LDN effects in HIV/AIDS in Mali, Africa
- LDN for fibromyalgia — a randomized, double-blind study at Stanford University
- LDN for Crohn’s disease — a Phase II, randomized placebo-controlled double-blinded study at Hershey Medical Center, Penn State College of Medicine